Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists and Oncologists in Private Practice (US)

Articles with lock require a subscription to GLG News | Request a free trial
November 18, 2008
Rash Predicts Better Outcome With Erbitux; But Will "Rash" Change Patient Care? Probably Not.
Analysis of: Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months | www.pipelinereview.com
Author: GLG Expert Contributor
It is important to use caution when interperting outcomes (in this case survival) in terms of post-treatment  (Erbitux) variables (rash).  It's a little like saying that patients who respond do better. Yes, it may be true that rash is an early indicator of which patients...
November 10, 2008
Avastin Likely To Be Rapidly Adopted for Treatment of Glioblastoma
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Glioblastoma (GBM) is a terrible diease with little chance of long term survival and few advancements in over the last few decades. While the recent study of Avastin in GBM was not a definitive study, data presented in the press release suggest that Avastin has clear activity in relapsed GBM...
October 28, 2008
Yes, Smaller Populations for Targeted drugs, but Pharma/Biotech AND Patients Win
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: GLG Expert Contributor
While targeting a drug to the right patients may in fact the decrease the size of the patient population for that drug, but several factors may actually result in benefit not only for patients, but for biotech/pharma companies, insurance companies and society.   When a drug is given...
October 27, 2008
Patient Education Critical Adjunct to Testing for Disease Risk
Analysis of: Study to Track How People React to Disease-Risk Data | online.wsj.com
Author: GLG Expert Contributor
Individual reactions to learning about disease-risk data range the gambit from denial, paranoia, disbelief, as well as relief in knowing, whether the outcome is positive or negative.    One of the most important implications is the need for physicians and other health care givers...
October 17, 2008
Everyone wins when patients get drugs they are most likely to offer a benefit
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Being able to select the right drug for the righ patient benefits everyone, most importantly patients, but also the drug company.  Developing drugs specifically for a small, but targeted population likley means you get a much higher level of efficacy for a smaller population making the risk-benefit...
September 25, 2008
Tomotherapy, Protons, Short Course Breast RT - ASTRO 2008
Analysis of: Hospitals Look to Nuclear Tool to Fight Cancer | www.nytimes.com
Author: GLG Expert Contributor
Tomotherapy may do well after all with newer bells and whistles introduced at ASTRO 2008. Protons are likely to die leaving investors with a huge bill and dwindling ROI. Short course breast radiotherapy is not worth the risk.
August 6, 2008
Cancer Diagnosis and Treatment Among High Profile Celebrities and Public Figures
Analysis of: Recent Popular New Reports About Senator Ted Kennedy's Brain Tumor | www.cnn.com
Author: GLG Expert Contributor
Nothing fascinates the public interest and imagination more than news about prominent and famous media stars who suffer illness or disaster. This is the way things are, but perhaps, at least in the case of healthcare issues, it could be beneficial to society to discuss these cases in detail, from both...
August 5, 2008
IT'S A SHAME!
Analysis of: As Doctors Cater to Looks, Skin Patients Wait | www.nytimes.com
Author: GLG Expert Contributor
Skin care encompasses cosmetic procedures.  But those cosmetic procedures should not take priority over the medical conditions - especially since dermatologists are uniquely qualified to treat them.  I didn't go to medical school, a residency in medicine, and a fellowship in dermatology to...
August 1, 2008
More of the Same Crackdown on Amgen's Epo Agents
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor
The FDA used new power to order Amgen to change its product label for its Epo Stimulating Agents (ESAs).  The new label will reflect what Medicare reimbursement guidelines have recently oulined.
July 9, 2008
This is not new news about Avastin
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Expert Contributor
Avastin is only one of many new targeted therapies that are expensive.  It was first introduced in colon cancer and has helped to extend the survival of metastatic colon cancer from 3-6 months to 2 years. It has recently been approved for use in lung and breast cancers as well.  It is in these...

Page : 1 2 3 4 5 6 Next1 to 10 of 55

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747